Targeting metabolic weaknesses in brain tumors with specific genetic changes
Targeting metabolic vulnerabilities induced by the 1p19q codeletion in oligodendrogliomas
['FUNDING_R21'] · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · NIH-10893486
This study is looking at a type of brain tumor called oligodendroglioma to find new, gentler treatments that can stop the tumor from growing by targeting its energy sources, which could help patients feel better with fewer side effects.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (nih funded) |
| Locations | 1 site (SAN FRANCISCO, UNITED STATES) |
| Trial ID | NIH-10893486 on ClinicalTrials.gov |
What this research studies
This research focuses on oligodendrogliomas, a type of brain tumor characterized by a specific genetic alteration known as the 1p/19q codeletion. The study aims to identify metabolic vulnerabilities in these tumors to develop targeted therapies that are less toxic than current treatments like chemotherapy and radiation. By inhibiting certain enzymes involved in tumor metabolism, the researchers hope to disrupt the growth of these tumors and improve patient outcomes. The approach involves using a combination of inhibitors to effectively target the tumor's energy production pathways.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with oligodendrogliomas that exhibit the 1p/19q codeletion.
Not a fit: Patients with other types of brain tumors or those without the 1p/19q codeletion may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less harmful treatment options for patients with oligodendrogliomas.
How similar studies have performed: Other research has shown promise in targeting metabolic pathways in cancer, suggesting that this approach could be effective for oligodendrogliomas as well.
Where this research is happening
SAN FRANCISCO, UNITED STATES
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO — SAN FRANCISCO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: VISWANATH, PAVITHRA — UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- Study coordinator: VISWANATH, PAVITHRA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.